Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Document › Details

Ablynx N.V.. (1/4/18). "Press Release: Ablynx to Present at the 36th Annual J.P. Morgan Healthcare Conference". Ghent.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
  Group Ablynx (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 Nanobodies®
Index terms Index term Ablynx–JPMorgan Chase: investor conference
  Index term 2 Ablynx–Consilium: public relations, 201406 service existent by Consilium
Persons Person Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
  Person 2 Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).

The presentation will be hosted by Dr Edwin Moses, CEO of Ablynx, and will be followed by a Q&A break-out session. The presentation will provide an overview of the major achievements in 2017 as well as an update on the Company’s proprietary key clinical assets, its partnered programmes and the outlook for 2018. During this conference, Ablynx will also hold one-on-one meetings with institutional investors.

The presentation will be webcast live and can be accessed on the day via this link. The presentation will be available on the Company’s website, under the News & Events section for 90 days following the event.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on

For more information, please contact:

Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68

Lies Vanneste
Director IR
t: +32 (0)9 262 0137
m: +32 (0)498 05 35 79


Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700

Record changed: 2018-01-09


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Ablynx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top